Regional chromosome localization of human papillomavirus intergration sites near fragile sites, oncogenes, and cancer chromosome breakpoints

https://doi.org/10.1016/0165-4608(88)90054-4Get rights and content

Abstract

The integration sites of human papillomavirus (HPV) DNA within the cervical carcinoma cell line C4-I and a primary cervical tumor were mapped by in situ hybridization. Cloned cellular sequences flanking the integrated viral DNA were used as probes. For the cell line, the viral integration site was mapped to chromosome region 8q21–q22.3, while in the primary tumor chromosome band 3p21 was the target for integration. The HPV DNA integration appears to occur in the vicinity of fragile sites, oncogenes, and chromosome breakpoints that are characteristic of hematologic malignancies and solid tumors. The integration of HPV may thus promote chromosome changes in cancer cells.

References (12)

  • F Hecht

    Fragile site update

    Cancer Genet Cytogenet

    (1988)
  • M Durst et al.

    A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions

  • M Boshart et al.

    A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer

    EMBO J

    (1984)
  • M Durst et al.

    The physical state of human papillomavirus type 16 DNA in benign and malignant tumors

    J Gen Virol

    (1985)
  • H Lehn et al.

    Papillomavirus genomes in human cervical tumors: Analysis of their transcriptional activity

  • T Matsukura et al.

    Cloning of monomeric human papillomavirus type 16 DNA integrated within cell DNA from a cervical carcinoma

    J Virol

    (1986)
There are more references available in the full text version of this article.

Cited by (93)

  • MicroRNAs are important players in head and neck carcinoma: A review

    2013, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    Integration of the HPVs seems to occur randomly throughout the whole host genome, mostly in non-coding sequences, having no pathogenic effect. However, some authors have speculated about its potential preference for sequences involving chromosomal fragile sites that harbor genes like the tumor suppressor FHIT at 3p14, the MYC protooncogene at 8q24, several loci within the hTERT promoter region at 5p15.14 [105–107], and many others. Interestingly, HPV-positive patients have totally different molecular characteristics than other HNSCC patients.

View all citing articles on Scopus

This work was supported by a program project grant on Fragile Sites and Cancer Cytogenetics (P01 CA-41124) from the National Cancer Institute.

View full text